GlassScriptPhysician profile
Amanda L Brenneman
NPI 1639658800
$1,103.49
in general payments reported to CMS, 2019-2025
15 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $30.18 · 2023: $209 · 2024: $228 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $295.66 | 2021-2025 | |
| Abbvie INC. | $265.28 | 2021-2025 | |
| Novo Nordisk INC | $125.60 | 2023-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $85.07 | 2021-2025 | Breztri, Airsupra |
| Abbott Laboratories | $64.03 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.60 | 2021-2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $40.29 | 2021-2022 | |
| Amgen INC. | $32.88 | 2021-2025 | Otezla, Repatha |
| Lilly USA, LLC | $30.23 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.01 | 2021-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $23.48 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $22.41 | 2021 | |
| Merck Sharp & Dohme LLC | $16.85 | 2023 | M-M-R II, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $16.56 | 2023 | Shingrix, Bexsero, Menveo |
| Idorsia Pharmaceuticals US INC | $15.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Brenneman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.